Back To: Home



June 6-7, 2013
European Lab Automation - Hamburg, Germany

June 12-15, 2013

More Events
Name:
Company:
Email:
 
 
 
PerkinElmer

Xencor, Boehringer Ingelheim partner on biosuperior antibodies
April 2012
SHARING OPTIONS:

MONROVIA, Calif.—Xencor Inc. and Boehringer Ingelheim recently announced a collaboration focused on certain of Xencor’s biosuperior monoclonal antibodies. Per the agreement, Boehringer Ingelheim will provide all manufacturing and product supply for development from preclinical through Phase I. For its part, Xencor will be responsible for preclinical and clinical studies, and will retain all development and commercial rights to products under the agreement. If clinical programs are successfully advanced past Phase I development, Boehringer Ingelheim will have certain manufacturing rights to supply Xencor with clinical and commercial material.
 
“Xencor and Boehringer Ingelheim will share the financial risk in early preclinical and clinical development with the incentive of sharing in future success of the programs,” Dr. Bassil Dahiyat, president and CEO of Xencor, said in a press release.

Back

cISBIO

Gilson


Beckman

eBiosciences

INDIGO

Drummond
CONTACT US
Drug Discovery News
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2013 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.